MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will present an overview of the company’s business at the Wedbush PacGrow Life Sciences 2015 Life Sciences Management Access Conference and at the Canaccord Genuity 2015 Growth Conference.
The presentation at the Wedbush PacGrow conference is scheduled for 9:45 A.M. ET on Tuesday, August 11, 2015 at the Le Parker Meridien in New York, and the Canaccord Genuity presentation is scheduled for Wednesday, August 12, 2015 at 11:30 A.M. ET at the InterContinental in Boston.
A replay of each presentation will be available via the investors section of the company’s website at www.intersectENT.com. The webcast replays will be archived for approximately one month.
About Intersect ENT
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL® and PROPEL® mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
Contacts
Inquiries:
Intersect ENT, Inc.
Jeri Hilleman,
650-641-2105
ir@intersectENT.com
